In a 26-year-old patient with elevated ferritin and severe diffuse fatty infiltration of the liver on ultrasound, what is the appropriate management?

Management of 26-Year-Old with Elevated Ferritin and Severe Fatty Liver

The immediate priority is to distinguish between true iron overload (hemochromatosis) and dysmetabolic hyperferritinemia from fatty liver disease by checking transferrin saturation, followed by non-invasive fibrosis assessment to determine disease severity and guide management.

Initial Diagnostic Workup

Determine the Cause of Hyperferritinemia

The first critical step is measuring transferrin saturation (TSAT) to differentiate iron overload from inflammatory hyperferritinemia:

• TSAT >45%: Suggests true iron overload (hemochromatosis) - proceed with HFE gene testing (C282Y and H63D mutations) 1
• TSAT <40-45%: Indicates dysmetabolic/inflammatory hyperferritinemia from NAFLD/MASLD, not iron overload 2, 3

In MASLD patients, hyperferritinemia occurs in approximately 26% of cases and reflects chronic inflammation and iron sequestration rather than true iron overload 4. A recent case demonstrated severe hyperferritinemia (1281-1642 ng/mL) with normal TSAT (23%) and normal liver iron concentration on MRI, confirming this pattern 2.

Assess Metabolic Risk Factors

Evaluate for metabolic dysfunction-associated steatotic liver disease (MASLD) components:

• Fasting glucose, HbA1c, HOMA-IR (insulin resistance)
• Lipid panel (triglycerides, HDL)
• BMI and waist circumference
• Blood pressure
• Uric acid levels

Patients with hyperferritinemia in MASLD typically show more severe metabolic dysfunction, higher triglycerides, HbA1c, insulin resistance, and liver enzymes 4.

Fibrosis Risk Stratification

Non-Invasive Assessment (Mandatory)

All patients require non-invasive fibrosis assessment at diagnosis 1:

1. Calculate FIB-4 score (age, platelets, AST, ALT) - best validated serum marker 1
2. Check for high-risk features:
   • Ferritin >1,000 µg/L
   • Elevated transaminases
   • Hepatomegaly
   • Thrombocytopenia

If ferritin <1,000 µg/L with normal transaminases and no hepatomegaly, the risk of advanced fibrosis is very low (94% negative predictive value) 1.

When to Pursue Advanced Imaging

Transient elastography (FibroScan) should be performed if:

• Ferritin >1,000 µg/L
• Elevated liver enzymes
• Abnormal FIB-4 score
• Clinical uncertainty about fibrosis stage

Liver stiffness <6.4 kPa effectively rules out advanced fibrosis 1.

Role of Liver Biopsy

Consider liver biopsy if 1:

• Ferritin >1,000 µg/L (strong recommendation)
• Elevated transaminases with ferritin <1,000 µg/L
• Cirrhosis cannot be confirmed or excluded by non-invasive means

Do NOT perform liver biopsy solely to diagnose hepatic iron overload - use MRI R2* quantification instead 1.

Management Based on Diagnosis

If True Iron Overload (High TSAT, Positive HFE):

1. Cardiac evaluation if severe iron overload: ECG and echocardiography 1
2. Therapeutic phlebotomy is the treatment of choice
3. MRI R2 quantification* can predict phlebotomy requirements 1

If MASLD with Dysmetabolic Hyperferritinemia (Normal TSAT):

There is NO conclusive evidence supporting phlebotomy in MASLD patients with metabolic syndrome or fatty liver disease 1. This is a critical pitfall to avoid.

Primary management focuses on:

• Weight loss (7-10% body weight target)
• Dietary modification (Mediterranean diet, reduce refined carbohydrates)
• Exercise (150 minutes/week moderate intensity)
• Optimize metabolic comorbidities:
  • Diabetes control
  • Lipid management
  • Blood pressure control
• Consider pharmacotherapy (GLP-1 agonists, pioglitazone) for NASH if indicated

Important Clinical Nuances

Ferritin as a prognostic marker: While elevated ferritin (>1.5× ULN) is independently associated with advanced fibrosis and NASH in some studies 5, 6, other research shows it is NOT predictive of fibrosis when used alone 7. The 2026 meta-analysis confirms hyperferritinemia identifies higher-risk MASLD phenotypes with more severe metabolic dysfunction and increased liver-related events (HR 2.02) 4.

Gender differences: Ferritin is significantly higher in males and different thresholds apply (>300 ng/mL women, >450 ng/mL men for >1.5× ULN) 5.

Pattern of iron deposition: If biopsy is performed, mixed hepatocyte and reticuloendothelial iron deposition is most strongly associated with NASH, while ferritin alone is not 8.

Follow-Up Strategy

• If low-risk (ferritin <1,000 µg/L, normal enzymes, no hepatomegaly): Monitor ferritin and TSAT annually; focus on lifestyle modification
• If intermediate/high-risk: Repeat elastography every 1-2 years; intensify metabolic management
• If cirrhosis confirmed: HCC surveillance with ultrasound ± AFP every 6 months